Alnylam Canada ULC is pleased to announce that OXLUMO® (lumasiran) is now funded across Canada through both public and ...

Alnylam Pharmaceuticals (Nasdaq: ALNY) has won European Commission approval for Amvuttra (vutrisiran) to treat transthyretin ...

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its target price hoisted by equities research analysts at Wells ...

Alnylam Pharmaceuticals ALNY +1.01% Get Free Report is currently in Phase 10 of its 18-phase Adhishthana Cycle. With this phase scheduled to end in September 2025, the stock remains within its bullish ...

The fact that multiple Alnylam Pharmaceuticals, Inc. ( NASDAQ:ALNY ) insiders offloaded a considerable amount of ...

Diversified Trust Co decreased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 40.3% during the ...

For payers, claims for rare disease treatments used to be uncommon. Not anymore, thanks to an increasing number of new, ...

Buying $1000 In ALNY: If an investor had bought $1000 of ALNY stock 5 years ago, it would be worth $2,172.18 today based on a price of $322.83 for ALNY at the time of writing.

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is among the best stocks added in a Growth Stock Portfolio.

With CT scans picking up more cases of sclerosing mesenteritis, be prepared to diagnose this poorly understood autoimmune ...

The growing incidence of infectious diseases, cancer, and chronic illnesses has substantially increased the demand for ...